ASH 2024

In oncology and hematology, success hinges on designing and executing trials that truly make a difference—from the start. At Syneos Health, we combine clinical innovation with deep therapeutic expertise to drive the success of your early-phase trials. As the go-to partner for early-phase oncology (EPO), we have supported over 300 EPO studies, with a dedicated team that understands the intricacies of both hematology and oncology trials. 

Meet with us at ASH 2024 to explore how Syneos Health can help you implement innovative adaptive trial designs and leverage cutting-edge biostatistical methods to optimize trial outcomes. 

Poster Presentation

Usage of Disease-Specific Patient Reported Outcome Measures (PROMs) for Assessing Quality of Life (QoL) in Industry Sponsored Hemophilia Interventional Trials

Daniel Mazzolenis, MD | Senior VP, Oncology & Hematology

Chris Keuker, MD | Executive Medical Director, Oncology & Hematology

Ana Baptista, MD | Senior Medical Director, Oncology & Hematology

Other Attendees

Patrick Kelly, MD | Vice President, Oncology & Hematology

Wael Harb, MD | Vice President, Oncology & Hematology

Related Content

Want to learn more? Explore Insights Hub for our latest perspectives, subscribe to our podcast, or click the resources below:  

End-to-End Expertise in Early-Phase Oncology​ 

Oncology Expertise at all Levels ​ 

Expertise in Nonmalignant Hematology ​ 

WEBINAR | Transforming Oncology Drug Development: Insights from Healthcare Providers on the Frontlines of Cancer Care